Not Signed In - Lenalidomide Enhances Effects Of Monoclonal Antibodies In B-Cell Lymphoma
Sun, 17 Dec 2006 05:00 PM EST
... Combining a new immunomodulating cancer drug - lenalidomide - with monoclonal antibodies - galiximab (anti-CD80 antibody) and campath (anti-CD52 antibody) - appears to have significant anticancer activity for patients with B-cell lymphoma in preclinical studies conducted at Roswell Park Cancer Institute. [click link for full article] ...
Related Topics
- Lymphoma
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Sickle Cell Anemia
- Lymphoma, Burkitt's
- Burkitt's Lymphoma
- Cutaneous T-Cell Lymphoma
- Stem Cell Research
- Cutaneous T-Cell Lymphoma, see Mycosis Fungoides and Sézary Syndrome
- Lymphoma, Cutaneous T-Cell, see Mycosis Fungoides and Sézary Syndrome
- T-Cell Lymphoma, Cutaneous, see Mycosis Fungoides and Sézary Syndrome
- Small Cell Lung Cancer
- Sickle Cell
- Skin Cancer
- Renal Cell Cancer
- Blood Cells
- Leukemia
- Adult Hodgkin's Lymphoma
- Hodgkin's Lymphoma, Adult
- Adult Non-Hodgkin's Lymphoma
email this page
print this page
bookmark this page
feedback on this page
